Profile

Gene Mack

interim Chief Financial Officer, Gain Therapeutics, Inc.

In the seat, on an interim basis. First published here October 28, 2026; built from records as of October 28, 2026.

Gene Mack has been interim Chief Financial Officer of Gain Therapeutics, Inc. since October 1, 2026, according to the company's filing of September 28, 2026.¹

The filing gives Gene Mack's previous role as President and Chief Executive Officer at Gain Therapeutics, Inc.¹ Gene Mack already worked at Gain Therapeutics, Inc. when appointed, so the record counts the move as an internal promotion.¹

Seats

The seat in the record

Company	Title as filed	Standing	Filings
Gain Therapeutics, Inc. (GANX) Pharmaceutical Preparations	interim Chief Financial Officer	In the seat, on an interim basis	1

Company names link to the company's page in the record at CFO Tribune, which holds the seat history.

The record

Filing by filing, latest first

October 1, 2026effective
Gain Therapeutics, Inc. named Gene Mack interim Chief Financial Officer, effective October 1, 2026. Profile of Gianluca Fuggetta.
On September 24, 2026, the Company’s board of directors appointed Gene Mack, the Company’s current President and Chief Executive Officer, to serve as the Company’s interim Chief Financial Officer, effective as of October 1, 2026.
[1] Filing by Gain Therapeutics, Inc., filed with the SEC on September 28, 2026. Read the filing. The record at CFO Tribune.

Sources

Current report filed with the SEC, Gain Therapeutics, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed September 28, 2026. sec.gov; record.

Corrections and removal

If a line here is wrong, or Gene Mack wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.